Dualtherapie mit Omalizumab (Xolair®) und Spezifische Immuntherapie (SIT) bei beruflich bedingter Mehlstauballergie mit Rhinokonjunctivitis allergica und allergischem Asthma bronchiale
Research output: Contribution to journal › Review article › Contributed › peer-review
Contributors
Abstract
The dual therapy with SIT and Omalizumab is effective and has a good safety and tolerability. Patients reported a significant subjective improvement of life quality without avoiding their work activity. Drug use resulted to be reduced. Therefore, patients will be adherent even when the treatment must be carried out throughout the entire working life.
| Translated title of the contribution | Dual therapy with Omalizumab (Xolair ®) and specific immunotherapy (SIT) in patients suffering from rhinoconjunctivitis allergica and persistent severe baker's asthma bronchiale caused by inhalation of cereal flour dust |
|---|
Details
| Original language | German |
|---|---|
| Pages (from-to) | 44-45 |
| Number of pages | 2 |
| Journal | Allergologie |
| Volume | 40 |
| Issue number | 2 |
| Publication status | Published - Feb 2017 |
| Peer-reviewed | Yes |
External IDs
| ORCID | /0000-0003-3894-1175/work/148603815 |
|---|
Keywords
ASJC Scopus subject areas
Keywords
- Allergic asthma bronchiale, Baker's asthma, Cereal flour allergy, Rhinitis allergica